#Cambridge #UK #Foventa Therapeutics #Zaiba Malik #Julia Jones

Foventa Therapeutics Strengthens Leadership Team

Foventa Therapeutics, a pioneering biotechnology firm that is dedicated to advancing treatments for retinal vascular diseases, has announced key appointments to its management team, signaling a robust commitment to innovation in the ophthalmology sector. Dr. Zaiba Malik has been appointed as the Chief Medical Officer (CMO), while Julia Jones steps in as the Chief Financial Officer (CFO). These strategic hires are aimed at propelling the company’s flagship product, FOV407, through critical phases of development and funding.

Harnessing Expertise in Ophthalmic Innovations

Dr. Zaiba Malik brings over two decades of rich experience in clinical ophthalmology and drug development to her new role at Foventa. Prior to her appointment, she served as the Global Medical Director and Therapeutic Area Lead for Ophthalmology at Medpace. Dr. Malik's extensive background includes a medical degree from the University of Miami School of Medicine and a residency in ophthalmology at Henry Ford Hospital in Michigan. Not only does she possess robust industry experience, but she also actively participates in clinical practice and humanitarian efforts, giving her a comprehensive understanding of patient needs and treatment advancements.

Julia Jones, who has an impressive track record working with biotech firms in both the US and Europe, has been appointed as the CFO. Her previous roles have seen her successfully guide startup companies through various stages of growth and exit, managing around £1.5 billion in venture capital funds. Her expertise extends to notable clients including Benuvia Operations Inc, PepGen Inc, and Congenica Ltd, positioning her well to support Foventa’s financial strategies.

Driving FOV407 Forward

The newly appointed duo will work closely with CEO Olav Hellebø to secure Series A funding, which is crucial for advancing FOV407 into its Phase IIb trial. This particular asset is poised to be a groundbreaking topical treatment for diabetic retinopathy, a condition that commonly arises among diabetes patients and can lead to severe vision impairment. Traditional approaches often involve invasive procedures and are generally reserved for later stages of the disease, making FOV407’s non-invasive delivery system a highly attractive alternative.

“We are thrilled to welcome Zaiba and Julia to the Foventa team,” stated Olav Hellebø, emphasizing the collective vision for FOV407 to redefine treatment options within the ophthalmology market. His confidence in their ability to make significant contributions to the company’s mission reflects a broader commitment to patient care and clinical excellence.

Foventa’s Commitment to Patient-Centric Solutions

Foventa Therapeutics is at the forefront of clinical-stage biotechnology, focused on innovative approaches that aim to preserve and restore sight through the development of cutting-edge ophthalmic medicines. The commitment to transformative patient care revolves around FOV407, designed to be accessible, non-invasive, and efficacious in managing diabetic retinopathy before irreversible damage occurs.

With an emphasis on research-driven solutions rooted in a deep understanding of retinal biology and related pathologies, Foventa combines scientific advancement with a strong patient-first philosophy. This vision is expected to not only advance eye care but also significantly improve the quality of life for patients affected by degenerative eye conditions.

In conclusion, the appointment of Dr. Malik and Ms. Jones marks a pivotal milestone for Foventa Therapeutics. Their leadership promises to steer the company through its next phases of growth, setting the stage for innovations that could redefine treatment paradigms in the ophthalmology sphere. More information about Foventa and its initiatives can be found on its official website, www.foventa.com.